Table 2.
Patients with lung tumors showing an NSCLC to SCLC transformation. ID number refers to the patient number in Table 1. Pre-, pre-treatment; Post-, posttreatment/drug-resistant.
| Age (years) | Gender | ID no. | Biopsy | Histology | Synaptophysin | Chromogranin | CD56 | Genotype |
|---|---|---|---|---|---|---|---|---|
| 67 | Female | 22 | Pre- | Adenocarcinoma | − | − | − | L858R |
| Post- | SCLC | + | + | + | L858R | |||
| 54 | Female | 23 | Pre- | Adenocarcinoma | − | − | Weak+ | Exon 19 deletion |
| Post- | SCLC | Strong+ | Exon 19 deletion | |||||
| 56 | Female | 24 | Pre- | Adenocarcinoma | − | − | L858R | |
| Post- | SCLC | + | + | L858R, PIK3CA | ||||
| 40 | Female | 25 | Pre- | Adenocarcinoma | − | − | − | Exon 19 deletion |
| Post- | SCLC | + | − | Exon 19 deletion | ||||
| 61 | Female | 26 | Pre- | Adenocarcinoma | − | − | − | L858R |
| Post- | SCLC | + | + | L858R |